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Abstract
To combat the possibility of a zoonotic H5N1 pandemic in a timely fashion, it is necessary to develop a vaccine that would
confer protection against homologous and heterologous human H5N1 influenza viruses. Using a replicating modified
vaccinia virus Tian Tan strain (MVTT) as a vaccine vector, we constructed MVTTHA-QH and MVTTHA-AH, which expresses the H5
gene of a goose-derived Qinghai strain A/Bar-headed Goose/Qinghai/1/2005 or human-derived Anhui Strain A/Anhui/1/
2005. The immunogenicity profiles of both vaccine candidates were evaluated. Vaccination with MVTTHA-QH induced a
significant level of neutralizing antibodies (Nabs) against a homologous strain and a wide range of H5N1 pseudoviruses
(clades 1, 2.1, 2.2, 2.3.2, and 2.3.4). Neutralization tests (NT) and Haemagglutination inhibition (HI) antibodies inhibit the live
autologous virus as well as a homologous A/Xingjiang/1/2006 and a heterologous A/Vietnam/1194/2004, representing two
human isolates from clade 2.2 and clade 1, respectively. Importantly, mice vaccinated with intranasal MVTTHA-QH were
completely protected from challenge with lethal dosages of A/Bar-headed Goose/Qinghai/1/2005 and the A/Viet Nam/
1194/2004, respectively, but not control mice that received a mock MVTTS vaccine. However, MVTTHA-AH induced much
lower levels of NT against its autologous strain. Our results suggest that it is feasible to use the H5 gene from A/Bar-headed
Goose/Qinghai/1/2005 to construct an effective vaccine, when using MVTT as a vector, to prevent infections against
homologous and genetically divergent human H5N1 influenza viruses.
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Introduction
Highly pathogenic avian influenza A virus (HPAIV) H5N1 has
long been carried by wild aquatic bird populations, spread
throughout the world via either the poultry transportation or the
migratory bird flyway, and has killed or led to the culling of
hundreds of millions of birds [1,2]. H5N1 was shown to be lethal
to human in 1997 when 6 of the 18 infected human cases in Hong
Kong died [3–5]. Although H5N1 viruses have not yet been
transmitted between humans, cross-species transmission of these
viruses to human has been documented in 633 cases, with a
mortality rate of 59.6%, since the reemergence of H5N1 viruses in
2003 [6]. Several recent independent studies suggested that H5N1
viruses might require very few amino acid substitutions to become
transmissible via respiratory droplets between mammals [7–9].
Therefore, great concern has been raised in the ability of H5N1
viruses to efficiently spread between humans and become a
pandemic threat, thus making an H5N1 influenza vaccine an
integral part of any pandemic preparedness plan [10].
Broad cross-protection is a highly desirable feature of an H5N1
vaccine to avoid the possible pandemic of H5N1 influenza viruses.
However, the efficacies of currently licensed vaccines appear to be
insufficient partially due to the antigenic diversity present in the
virus, restricting the utility of the vaccine to a small number of
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specific strains. Whilst the identity of any specific pandemic strain
is rather difficult to predict before the event, it would take 4–6
months or more to deliver a vaccine using current manufacturing
technologies [11,12]. Therefore, great efforts have been made
toward developing vaccines with broad cross-protection against
H5N1 influenza viruses, as well as improving vaccine production
methods to shorten the lead-time to vaccine delivery. New
approaches, such as virus-like particles (VLPs), naked DNA and
adenoviral and vaccinia vector-based vaccines have been devel-
oped to prevent H5N1 viral infections [10,13,14]. It was reported
that inactivated H5N1 influenza viruses of clades 1 and 2.1 and
virus-like particles (VLPs) containing the HA, NA and M1 proteins
of IN5/05 and VN/1203 showed significant cross-protective
potential [15–17]. Non-replicating vaccinia vectors, such as the
Modified Vaccinia Virus Ankara (MVA) carrying an HA derived
from the VN/1203 strain, displayed a high level of cross-
protection [18]. A veterinary vaccine expressing the H5 gene of
the A/Bar-headed Goose/Qinghai/1/2005 (A/BhG/QH/1/05)
also provided protection against lethal challenges of homologous
and heterologous avian H5N1 influenza viruses [19].
In our previous study, we generated a replicating Modified
Vaccinia Tian Tan (MVTT) from Vaccinia Tian Tan (VTT) by
removing the hemagglutinin gene and an 11,944bp genomic
region from the HindIII fragment C2L to F3L in VTT [20]. VTT
has been used extensively as a smallpox vaccine for millions of
people in China before the 1980’s [21] and was successfully
developed into a vaccine vector for rabies and hepatitis B viruses
[22,23]. Compared to VTT, MVTT is very safe, as it has been
shown to not replicate in mouse brain and does not cause death
after intracranial injection or body weight loss after intranasal
inoculation in immuno-deficient mice [20]. Moreover, using the
spike glycoprotein (S) of SARS-CoV as the test antigen, we found
that MVTT is superior to MVA for inducing high levels of
neutralizing antibody via mucosal vaccination [24]. In this report,
using MVTT as a live vaccine vector, we constructed MVTTHA-
QH and MVTTHA-AH, which expresses the H5 gene of a goose-
derived Qinghai strain A/Bar-headed Goose/Qinghai/1/2005 or
human-derived Anhui Strain A/Anhui/1/2005. We determined
the immunogenicity and efficacy of both vaccine constructs in
mice against homologous and heterologous human H5N1
influenza viruses.
Materials and Methods
Our experimental protocols were approved by The Institutional
Animal Care and Use Committee (IACUC) of the Chinese
Academy of Military Medical Science, Beijing, China.
Viruses and cells
HAXJ/WSN stands for the recombinant influenza A virus with
its HA gene derived from the human strain A/Xingjiang/1/06
(H5N1) and the other seven genes from A/WSN/33 (H1N1). This
reverse genetics system was kindly provided by Yoshiro Kawaoka
[25]. Two wild-type H5N1 influenza viruses, A/BhG/QH/1/05
and A/Vietnam/1194/2004 (A/VN/1194/04), were used for
challenge in this study. A/BhG/QH/1/05 and A/VN/1194/04
were cultivated in 10-day-old embryonated SPF chicken eggs
(Beijing Merial Vital Laboratory Animal Technology Co., Ltd.,
Beijing, China), while A/HAXJ/WSN was propagated on Madin-
Darby canine kidney (MDCK) cells. MDCK cells and Vero cells
were cultured in Dulbecco’s modified Eagle’s minimum essential
medium (DMEM) supplemented with 10% fetal calf serum (FCS)
at 37uC in an atmosphere of 5% CO2. Allantoic fluids and cell
cultures were harvested and stored at 270uC. The fifty percent
mouse lethal dose (MLD50) of each strain was determined in 6-
week-old female BALB/c mice and the fifty percent tissue culture
infectious dose (TCID50) was titrated in MDCK cells. All of these
experiments were conducted in a bio-safety level-3 laboratory. A
group of diverse H5N1 pseudoviruses were prepared according to
recently described methods [10].
Construction of recombinant MVTTHA-QH and MVTTHA-AH
The HA gene of A/BhG/QH/1/05 was amplified from the
total RNA of the virus by RT-PCR. The HA gene of A/Anhui/1/
2005 was kindly provided by Dr. David Ho and amplified by
PCR. Each HA ORF gene was then inserted into a vaccinia
shuttle vector pZCXZ under the strong synthetic promoter pSYN
and subsequently recombined into the promoter region of the
MVTT HA gene to generate MVTTHA-QH and MVTTHA-AH
using a homologous recombination method by transfection, as
previously described [26]. In brief, Vero cells were infected with
MVTT and subsequently transfected with a shuttle vector pZCxz
containing the HA gene of influenza H5N1 flanked with MVTT
HA sequences [26]. The recombinant virus was selected through
six rounds of plaque purification under agar and confirmed by
immunostaining assay using an anti-H5 serum [26]. The insertion
of full length gene of H5N1 HA was further confirmed by PCR
using specific primers. Total DNA was extracted from MVTTHA-
QH, MVTTHA-AH or MVTTSIV infected Vero cells as described
before [24]. The presence of full-length H5N1 HA genes were
evidenced by the amplification of around 1700 bp fragments using
the following pairs of primers: Anhui-F 59-ATGGAGAA-
GATCGTGCTGCTG, and Anhui-B 59-GATGCAGATTCTG-
CACTGCAGGCT; Qinghai-F 59 ATGGAGAAAATAG-
TGCTTCT: Qinghai-B 59 AATGCAAATTCTGCATTGTA,
respectively. MVTTHA-QH and MVTTHA-AH viral stocks were
propagated in Vero cells and then purified by ultracentrifugation
through a 36% sucrose cushion. Both viral stocks were titrated
simultaneously in Vero cells by a plaque forming assay using
crystal violet staining or counting the plaques with GFP expression
[26].
Animal immunization
Six-week-old female BALB/c mice were used in all animal
experiments. Three groups of mice (5 in each group) were
immunized with 3.06106 plaque formation unit (PFU) of
MVTTHA-QH or MVTTHA-AH through intranasal, intramuscular
or oral routes at day 0 and day 31, respectively. The same number
of mice was included in control groups given either PBS or
MVTTS. MVTTS is a recombinant virus expressing the spike
glycoprotein of SARS-CoV, as we recently described [24]. Blood
samples from each mouse were collected 2 weeks after each
vaccination for measurement of antibody responses. Splenocytes
were also collected for measuring cell-mediated immune response
after stimulation with an H-2Kd-restricted T-cell epitope IYST-
VASSL, as previously described by others [27].
Detection of immune responses
Sera from mice were treated with receptor-destroying enzyme
(RDE, purchased from the Institute of Viral Disease Control and
Prevention, Chinese Center for Disease Control and Prevention)
in the ratio of 1:3 and heat-inactivated for 30 minutes at 56uC.
Neutralization tests (NT) using the diverse H5N1 pseudoviruses
was performed according to recently described methods [10].
Haemagglutination inhibition (HI) tests were performed with 1%
chicken red blood cells according to a method recommended by
the World Organization for Animal Health (http://www.oie.int/
Eng/Normes/Mmanual/A_00037.htm). Serum samples were also
Avian-H5 Vaccine Protects Human H5N1 Viruses
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tested for neutralizing antibody against live A/BhG/QH1/05, A/
HAXJ/WSN and A/VN/1194/04 by a traditional micro-neutral-
ization assay. Briefly, heat-inactivated sera were first two-fold
diluted with DMEM, and then mixed with an equal volume of 100
TCID50 of each of H5N1 influenza viruses. After an incubation
period of 1 hour at 37uC, 200 ml of serum-virus mixtures were
transferred onto MDCK cells in a 96-well plate, in triplicates.
These cells were observed for any cytopathic effect (CPE), daily for
3 consecutive days. The titer of neutralizing antibody was defined
as the highest serum dilution that inhibits the formation of 50%
CPE. The cell-mediated immune response was determined by
measuring H5-specific IFN-c released by splenocytes according to
a previously published ELIspot assay [10].
Protection of mice against viral challenge
Mouse models have been commonly used for evaluating
vaccines for influenza A (H5N1) viruses isolated from humans
[28]. Groups of nine mice were either immunized with 1.56106 or
3.06106 PFU of MVTTHA-QH and MVTTS, respectively, twice,
with a one month interval. Immunized mice were challenged with
either 100 MLD50 of A/BhG/QH/1/05 or 100 MLD50 of A/
VN/1194/04 at 3 weeks post second immunization. Body weight
change, number of deaths and clinical signs were closely
monitored after viral challenge twice a day. The animals were
humanely euthanized by intraperitoneal injection of pentobarbital
sodium salt (100 mg/kg) and followed by cervical dislocation,
when weight loss is greater than 20% body weight at the start of
the experiment for 72 hours. Pentobarbital sodium salt was used
to minimize suffering of the animals. The percentage of survival
was calculated as previously described [10].
Viral isolation
To measure viral replication in vivo, tissue samples (brain and
lung) were taken from two mice in each group for viral isolation on
the 3rd and 6th day post infection, respectively. After tissue samples
were weighed and homogenized, 0.1 ml of each supernatant was
inoculated into the allantoic cavity of 10 day-old embryonated
SPF chicken eggs. The allantoic fluids were subsequently harvested
and the HA activity was tested for the detection of virus
replication.
Statistical Analysis
Animal experiments to evaluate immune responses were
repeated at least twice (n=5 per group). The response of each
mouse was counted as an individual data point for statistical
analysis. Virus challenge studies were performed twice (n=5 or 9
per group). Data obtained from animal studies and pseudotyped
virus neutralization assays were examined by using one-way
ANOVA. Differences were considered significant at P,0.05.
Results
Design and construction of MVTT viruses expressing H5
hemagglutinins
The HA gene of A/BhG/QH/1/05 and A/Anhui/1/2005
were chosen for vaccine construction because A/BhG/QH/1/05
represents the prototype of clade 2.2 highly pathogenic influenza
A H5N1 viruses, which has led to sporadic human infections
around the world (Fig. 1), whilst A/Anhui/1/2005 is a WHO
recommended vaccine strain isolated from a human patient, which
may induce a better immune response against human isolates. We
analyzed the sequences of the HA genes derived from the human
A/Xingjiang/1/06 strain and those from other countries. When
compared with the HA of A/BhG/QH/1/05, the major antigenic
sites within clade 2.2 were relatively conserved despite viral
evolution occurring over two to three years outside the Qinghai
Lake area (Table 1). A/Anhui/1/2005 belongs to clade 2.3.4, in
which the major antigenic sites are very different from clade 2.2,
but rather conserved within clade 2.3.4. We hypothesized that
vaccines based on the HA would at least offer protection to human
H5N1 influenza viruses of the same clade.
A modified shuttle vector pZCxz was constructed to target the
H5N1 HA gene into the MVTT genome in the location of the
MVTT HA gene. This shuttle vector contains dual promoters that
allow the simultaneous expression of two target genes. Within this
vector, the HA gene of A/BhG/QH/1/05 or A/Anhui/1/2005
was constructed under the strong synthetic promoter pSYN,
whereas a reporter GFP or RFP gene was under a separate
relatively weaker promoter pH 5 (Fig.2A). Since both genes were
included within the same insertion frame, the reporter gene served
as a surrogate marker for the selection of recombinant VTT
carrying the HA gene. Using this technique, we were able to
generate and to purify the recombinant virus MVTTHA-QH and
MVTTHA-AH. The positive plaque was selected under a fluores-
cence microscope and subsequently confirmed by immunohisto-
chemcal staining assay using a mouse anti-H5 serum (Fig. 2B). To
further confirm that the full length H5N1 H5 gene was inserted
into the MVTT vector, the total DNA was extracted from Vero
cells infected by either MVTTHA-QH or MVTTHA-AH. Total DNA
was extracted from MVTTSIV infected Vero cells as negative
control. The full-length H5N1 HA genes were amplified from the
total DNA extracted from both MVTTHA-QH and MVTTHA-AH
infected cells using specific primers, but not MVTTSIV infected
Vero cells (Fig. 2C). These results confirmed that we have
successful constructed MVTT virus expressing H5 gene from A/
BhG/QH/1/05 and A/Anhui/1/2005 strains, respectively.
MVTTHA-QH induced specific immune responses against
homologous H5N1 influenza virus
To determine the immunogenicity of MVTTHA-QH and
MVTTHA-AH, two groups of mice were immunized twice with
36106 PFU of recombinant virus on day 0 and day 31, via the
intranasal (I.N.) and intramuscular (I.M.) routes, respectively.
Serum samples collected on day 0 and day 28 after the first
immunization and 2 weeks after the second inoculation (day 45)
were subjected to a neutralization (NT) assay by using a previously
described pseudoviral assay [10]. We found that MVTTHA-QH
was able to induce potent NT response against the autologous viral
strain with a dilution factor of IC50 over 1000 after the first
immunization (Fig. 3A). The I.N. route induced seemingly higher
levels of NT responses than the I.M. route after the first
immunization (IC50 titer: 4076 vs. 1326). Moreover, the second
immunization boosted primary responses by 2 (I.N.) to 8 (I.M.)
fold for NT titers. Mice who received the control MVTTSIV did
not generate any responses, as expected (Fig. 3A). In contrast, after
the 2nd immunization, none of the mice immunized with
MVTTHA-AH was able to induce any NT response against its
homologous strain (Fig. 3B). We, therefore, conducted a 3rd
immunization with the same dose of MVTTHA-AH three weeks
after the 2nd immunization, but only one in five mice was able to
produce NT responses against its homologous strain (IC50 titer:
70). However, MVTTHA-AH was able to induce potent NT
responses with a dilution factor of IC50 around 1000 after the 2nd
immunization against the Qinghai strain (Fig. 3C). Furthermore,
compared to MVTTHA-QH, MVTTHA-AH induced seemingly
lower levels of NT responses through the I.N. route than through
the I.M. route after the 2nd immunization. The 3rd immunization
boosted the primary responses for NT titers. These results suggest
Avian-H5 Vaccine Protects Human H5N1 Viruses
PLOS ONE | www.plosone.org 3 December 2013 | Volume 8 | Issue 12 | e83274
that immunization with MVTTHA-AH was successful, however, A/
Anhui/1/2005 is likely to be less sensitive to the neutralizing
activity of vaccine-induced antibody. Moreover, HA from A/
Anhui/1/2005 is less antigenic compared to HA from the Qinghai
strain.
We then chose MVTT-HA-QH for the evaluation of cell
mediated H5-specific responses. We found that both routes of
vaccination were able to induce H5-specifc IFN-c releasing CD8+
T-cells by measuring the spot forming counts (SFC) using ELIspot
assay (Fig. 3D). On average, about 420 SFC (I.M.) and 250 SFC
(I.N.) were detected among one million splenocytes. Thus,
MVTTHA-QH was found to be immunogenic in mice for inducing
both antibody and cellular immune responses and a better vaccine
candidate for the prevention of the H5N1 pandemic compared to
MVTTHA-AH. We, therefore, chose MVTT-HA-QH for further
evaluation.
Neutralizing antibodies induced by MVTTHA-QH inhibited
a wide range of divergent H5N1 influenza pseudoviruses
To further determine the cross-clade NT activities of MVTTHA-
QH, we tested the immune sera against a group of divergent H5N1
influenza pseudoviruses. The group included viruses from clades 1
(VN1203 and VN1194), 2.1 (ID05 and ID04), 2.2 (Qinghai and
Turkey), 2.3.2 (Chinese duck E319) and 2.3.4 (Fujian and Anhui)
(Fig. 1 and Table 1). Although the levels of cross-neutralization
varied, the Nabs induced by MVTTHA-QH were able to neutralize
pseudoviruses from all major clades tested (Fig. 4). Those viruses
from clade 2.2 were most optimally inhibited, followed by clades
2.1, 2.3.2, 2.3.4 and 1, which is consistent to the amount of
sequence variation at the antigenic sites (Table 1).
Figure 1. Phylogenetic relationship of the HA genes of influenza H5N1 viruses of multiple clades. This Neighbor-Joining tree is
constructed using a computer program implemented in the ClustalX program (version 2.0) as previously described [42]. The clade classification is
according to the reference sequences recommended by WHO. The asterisks highlight the vaccine strains recommended by WHO. Human isolates are
italicized. The three live viruses that are included in this study are marked with arrowheads.
doi:10.1371/journal.pone.0083274.g001
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Table 1. Sequence variation of HA gene of H5N1 influenza viruses at the indicated antigenic sites.
Amino acid residue at the indicated antigenic site and position
Clade Virus E B RBS A B Gly B D E C
86 94 124 129 138 140 155 156 174 181 183 189 212 227 263 269 277 282 310 322
2.2 A/BHG/Qinghai/1/2005* A N D S Q R N A V P D R K E T L K I R Q
2.2 A/Xingjiang/1/06 V . . . . . . T . . . . . . . . . . . .
2.2 A/Egypt/2321NAMRU3/2007 . D . . . . . . . . . . . . . . . . . .
2.2 A/turkey/Turkey/1/2005* . . . A . . . . . . . . . . . . . . . .
2.2 A/WS/Mongolia/244/2005* . . . . . . . . . . . . . . . . . . . .
2.1 A/Indonesia/5/2005* T S . . L S S T . . . . . . A . . M . .
2.1 A/Chick/Indonesia/5/2004 . . . . . K S T . . . . . . A . . M . .
2.3.4 A/Anhui/1/2005* . . . . . T . T I S . K . D A V . . K L
2.3.4 A/duck/Fujian/1734/2005 . . . . . T . T I S . K . D A V M . K L
2.3.4 A/duck/Laos/3295/2006* . . . . . T . T I S . K . D A V . . K L
2.3.4 A/Jpn-WE/HK/1038/2006* . . . . . T . K I S . K . D A V . . K L
2.3.2 A/duck/China/E319-2/03 . . . . . S D . . . . . . D A V . M K .
1 A/Hong Kong/213/03 . D S L . K . . . . . . . . A . . M . .
1 A/Vietnam/1194/2004* V D S L . K S T . . . K R . . . . M . .
1 A/Vietnam/1203/2004* V D S L . K S T . . . K R . . . . M . .
1 A/Cambodia/R0405050/2007 V D S L . K . T . . . N R . . . . M . .
Notes: The amino acid positions are based on mature H5 sequences. Three live viral strains that are included in this study are in bold.
Human isolates are in italic. The asterisk indicates a few WHO-recommended vaccine strains.
Abbreviations: RBS, receptor binding site; Gly, glycosylation site; BHG, bar-headed goose; Jpn-WE, Japanese white-eye.
doi:10.1371/journal.pone.0083274.t001
Figure 2. The schematic representation of MVTT-HA-QH and MVTT-HA-AH construction and the expression of the HA protein in cells
infected with MVTT-HA-QH or MVTT-HA-AH. (A) The HA gene was introduced, together with GFP gene or RFP gene, each under a separate promoter,
into the genome of MVTT. The restriction enzymes Bam HI and Xho I were used for constructing MVTT-HA-QH and MVTT-HA-AH. The insertion region
corresponds to the Del III region of MVA. (B) The HA protein was detected on Vero cells infected with MVTT-HA-QH or MVTT-HA-AH using mouse anti-HA
serum in an immunohistochemical staining assay. No HA protein expression was detected on Vero cells infected with the control virus MVTTSIV. (C) The
full length HA gene was detected in the total DNA extracted from Vero cells infected MVTT-HA-QH and MVTT-HA-AH using specific primers for H5N1
Qinghai or Anhui strain. No H5 gene was detected in total DNA extracted from Vero cells infected control virus MVTT SIV using both primers.
doi:10.1371/journal.pone.0083274.g002
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MVTTHA-QH induced potent antibody response and
protected mice against live homologous H5N1 influenza
virus
To further determine the efficacy of vaccination, three groups of
mice were immunized twice with 36106 PFU of MVTTHA-QH on
day 0 and 31, via the intranasal, intramuscular and oral
administration routes, respectively. We included the oral route,
as it is one of the easiest methods of vaccination for resource-
limited settings. Serum samples collected on day 0 before
vaccination, day 28 after the first immunization and 2 weeks after
the second inoculation (day 45) were subjected to HI and NT
assays using the live homologous A/BhG/QH/1/05 strain. We
found that all three vaccination routes were able to induce both HI
and NT responses (Table 2). The I.N. route induced seemingly
higher levels of both HI and NT responses than the other two
routes after the first immunization. Moreover, the second
immunization boosted the primary responses significantly, more
specifically, 4–16 fold for HI and 5–7 fold for NT titers, which are
consistent to findings using the pseudoviral neutralization assay
(Fig. 3A). Unexpectedly, two of the five mice in the oral group did
not respond to the vaccine after two immunizations for unknown
reasons. For the control, mice receiving PBS did not generate any
responses, as expected. We did not conduct the ELIspot assay in
this experiment because the animals were kept for subsequent viral
challenge.
To determine whether the vaccine would offer any protection,
vaccinated animals were challenged with the homologous patho-
genic A/BhG/QH/1/05 virus strain three weeks after the second
immunization. By evaluating the body weight change and the
survival rate, we found that all animals with detectable antibody
responses were completely protected (Fig. 5). Moreover, the
protected mice exhibited no clinical signs of infection, including
huddling, shivering and ruffled fur. In contrast, animals who
received PBS and the two mice (2/5) that did not show any
detectable antibody responses in the oral group, showed significant
clinical signs of infection and died within 6 days post viral
challenge.
Figure 3. HA-specific Nab and IFN-c-secreting CD8+ T-cell responses to MVTTHA-QH or MVTTHA-AH vaccinations. BALB/c mice were
vaccinated three times or twice with MVTTHA-QH (A) or MVTTHA-AH (B, C), respectively, at three-week intervals via intranasal (I.N.) and intramuscular
(I.M.) inoculations, respectively. The antiserum was collected at two weeks after each vaccination for analysis of HA-specific Nabs against H5N1
Qinghai strain (A, C) or Anhui strain (B), respectively. Control animals were given MVTTS via the same corresponding routes. (D) Splenocytes of
immunized mice were obtained after two immunizations and assessed by an ELIspot assay using a specific peptide (HA 9mer) or an irrelevant peptide
(HIV Gag 9mer). P,0.01, MVTTHA-QH vs. MVTTS.
doi:10.1371/journal.pone.0083274.g003
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MVTTHA-QH induced potent antibody response and
protected mice against live heterologous human H5N1
influenza viruses
To determine whether or not MVTTHA-QH would confer
protection against heterologous human H5N1 influenza viruses,
we immunized another four groups of mice via the I.N. and I.M.
routes. Here, we included the mock vaccine MVTTS for
determination of whether the vaccine vector would induce any
non-specific protection effects. Using the same vaccination
protocol, but with a reduced dosage (1.56106 PFU of
MVTTHA-QH), MVTTHA-QH was able to induce both HI and
NT responses, as expected (Table 3). In addition to the
Figure 4. Cross-neutralization of the infectivity of HA-pseudotyped viruses by antisera obtained from mice after receiving two
injections of MVTTHA-QH. The IC50 is defined as the mean reciprocal of the antiserum dilution at which virus entry is 50% inhibited (dashed line).
Data were collected from three independent experiments and the mean values are presented.
doi:10.1371/journal.pone.0083274.g004
Table 2. The antibody level of immunized mice via HI and NT
experiments.
0 dpv{ 28 dpv 45 dpv
Groups* Dose (pfu) HI NT HI NT HI NT
PBS (i.n.) N/A 0 0 0 0 0 0
rVTT-HA(i.m.) 36106 0 0 23 120.7 27 623.25
rVTT-HA (i.n.) 36106 0 0 25 163 27 1112.5
rVTT-HA (oral)` 36106 0 0 0, 23 0, ,40 0, 28 0, 1778
*, i.n.: intranasal. i.m.: intramuscular.
{dpv: day post primary vaccination.
`the separated values represent different antibody levels were detected. N/A:
not available.
doi:10.1371/journal.pone.0083274.t002
Figure 5. Vaccine protection against lethal challenge of
pathogenic A/BhG/QH/1/05 virus. BALB/c mice were vaccinated
twice with MVTTHA-QH via intranasal, oral and intramuscular routes,
respectively. The vaccinated animals were challenged with 100 MLD50
A/BhG/QH/1/05 three weeks after the second immunization. Mice who
received PBS were used as controls.
doi:10.1371/journal.pone.0083274.g005
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homologous virus, two heterologous human viruses, A/VN/1194/
04 and A/HAXJ/WSN, were included for testing. Consistent to
antigenic analysis (Table 1), similar levels of HI and NT responses
were detected against A/HAXJ/WSN when compared with the
homologous virus (Table 3). Despite antigenic variation, HI and
NT responses were also detected against the clade 1 A/VN/1194/
04 (Fig. 1 and Table 3). As expected, no H5-specific HI and NT
responses were detected among mice immunized with MVTTS.
To further determine the efficacy of MVTTHA-QH, the
vaccinated animals were challenged with pathogenic A/BhG/
QH/1/05 and A/VN/1194/04 viruses 3 weeks post second
immunization. Since A/HAXJ/WSN is not a pathogenic virus, it
was not included in the challenge experiment. Consistent to our
previous findings (Fig. 5), all animals with detectable antibody
responses were completely protected against the homologous A/
BhG/QH/1/05 challenge (Fig. 6A). Again, the protected mice
exhibited no clinical signs of infection. Importantly, all animals
with detectable antibody responses were also completely protected
against the heterologous A/VN/1194/04 challenge (Fig. 6B). In
contrast, animals which received MVTTS showed significant
clinical signs, including huddling, shivering, ruffled fur and body
weight loss, and most of them died within 6 days post viral
challenge. Despite the occurrence of clinical signs, three control
animals (one in the I.M. group and two in the I.N. group) survived
the A/VN/1194/04 challenge for unknown reasons (Fig. 6B).
To determine whether the MVTTHA-QH-induced immune
responses could prevent viral replication in vivo, two mice from
each group were sacrificed on days 3 and 6 post challenge with A/
BhG/QH/1/05 and A/VN/1194/04, respectively. Samples from
the lung and brain were then subjected to viral isolation. In
agreement with the data shown in Fig. 5, no viruses were obtained
from mice vaccinated with MVTTHA-QH (Table 4). In contrast,
viruses were readily isolated from mice who received MVTTS.
Interestingly, on day 3 post viral challenge, A/BhG/QH/1/05
was easily detected, whereas A/VN/1194/04 was not, suggesting
the higher infectivity and likely higher pathogenicity of the former
virus in the murine model.
Discussion
In this study, we investigated the breath and efficacy of two
MVTT based vaccines expressing H5 derived from A/Bar-headed
Goose/Qinghai/1/2005 or A/Anhui/1/2005 against homolo-
gous and heterologous human H5N1 influenza viruses. HPAIV
has been considered a serious public health threat with pandemic
potential. If an HPAIV pandemic occurs, it is estimated to claim
the lives of over a hundred million people [29,30]. However,
currently licensed vaccines are only effective to a small number of
specific strains. The difficulty to predict the pandemic strain
together with long and slow process of vaccine production make
the efficient development of a vaccine with broad cross-protection
an important step for pandemic preparedness. Here, we describe a
Modified Vaccinia Virus TianTan strain (MVTT) based H5N1
vaccine, expressing the H5 gene of a goose-derived Qinghai
strain A/Bar-headed Goose/Qinghai/1/2005, which can induce
Table 3. Antibody titer against homologous and
heterologous H5N1 influenza viruses.
BhG/QH/1/05 VN/1194/04 HAXJ/WSN
HI* NT HI NT HI NT
rVTT-HA (i.n.) 26 501.5 23 316 26 668.8
rVTT-HA (i.m.) 27 819.6 24 425 27 914.5
rVTT-S (i.n.) 0 0 0 0 0 0
rVTT-S (i.m.) 0 0 0 0 0 0
*Serum samples were collected and tested two weeks after the second
vaccination.
doi:10.1371/journal.pone.0083274.t003
Figure 6. Vaccine protection against lethal challenges of
homologous A/BhG/QH/1/05 (A) and heterologous A/VN/
1194/04 (B) viruses. BALB/c mice were vaccinated twice with
MVTTHA-QH via intranasal and intramuscular routes, respectively. The
vaccinated animals were challenged with 100 MLD50 of either A/BhG/
QH/1/05 or A/VN/1194/04 three weeks after the second immunization.
Mice who received MVTTS were included as controls.
doi:10.1371/journal.pone.0083274.g006
Table 4. Viral isolation in mice post lethal challenge with
BhG/QH/1/05 and VN/1194/04.
BhG/QH/1/05 VN/1194/04
3 dpi* 6 dpi 3 dpi 6 dpi.
MVTT-HA (i.n.) 0/2** 0/2 0/2 0/2
MVTT-HA (i.m.) 0/2 0/2 0/2 0/2
MVTT-S (i.n.) 2/2 2/2 0/2 2/2
MVTT-S (i.m.) 2/2 2/2 0/2 1/2
*, dpi: day post infection.
**, Two mice from each group were sacrificed for viral isolation at the indicated
time points.
The fractions in the cells present the number of mouse (mice) with virus
isolated/the number of mice from which tissue samples were collected.
doi:10.1371/journal.pone.0083274.t004
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broadly neutralizing antibodies and cross-clade protective immu-
nity in mice.
Currently, human vaccines have mainly focused on clade 1
strains, among which VNM/1203/04-based vaccines are the most
extensively studied. In contrast, both A/BhG/QH/1/05 and A/
Anhui/1/2005, although recommended by the WHO (World
Health Organization) as one of the vaccine targeted strains, have
yet to be comprehensively studied for their potential as a human
vaccine candidate. In the past few years, viruses that are closely
related to A/BhG/QH/1/05 have been found to have spread
rapidly to Europe, India and Africa via migratory birds, and were
likely the causative agents for several human infections throughout
Europe and China, including our recently identified A/Xinjiang/
1/06 [31–33]. In this study, we characterized the immunogenicity
of MVTTHA-QH and MVTTHA-AH, and the antibody response
induced against multiple H5N1 influenza viruses representing
clades 1 (VN1203 and VN1194), 2.1 (ID05 and ID04), 2.2
(Qinghai and Turkey), 2.3.2 (Chinese duck E319) and 2.3.4
(Fujian and Anhui) (Fig. 1) using the pseudoviral NT assay. We
found that Nabs induced by MVTTHA-QH neutralized pseudo-
viruses from all major clades tested. The MVTTHA-QH-induced
serum inhibited viruses from clade 2.2 most optimally, followed by
clades 2.1, 2.3.2, 2.3.4 and 1, suggesting that sequence variation in
the antigenic sites probably accounted for the reduced NT titers of
divergent H5N1 strains (Table 1). Moreover, we characterized a
MVTTHA-QH -induced antibody response against the human A/
Xinjiang/1/06 strain (Fig. 1), a virus recently identified from a
Chinese patient in Xinjiang province that is northwest to the
Qinghai province. Despite sequence variations in the antigenic
sites, probably due to adaptive infections in humans (Table 1), the
HA gene of A/Xinjiang/1/06 remains closely related to A/BhG/
QH/1/05 (Fig. 1). It is, therefore, not surprising to see that
MVTTHA-QH induced neutralizing and HI antibody responses
that reacted equally well against both A/BhG/QH/1/05 and
HAXJ/WSN (Table 3). In particular, the A86V and A156T
mutations in A/Xinjiang/1/06 did not seem to confer resistance
to the NT and HI antibodies induced by MVTTHA-QH (Table 1).
Furthermore, we determined the cross-reactivity of MVTTHA-QH–
induced NT and HI antibodies against another human virus, the
clade 1 A/VN/1194/04. Interestingly, although ten major
antigenic mutations were identified between A/BhG/QH/1/05
and A/VN/1194/04 (Table 1), which accounted for titer drops in
HI (,8-fold) and live viral NT (,2-fold) assays (Table 3),
MVTTHA-QH was still able to induce significant levels of NT
and HI antibody responses against the heterologous human A/
VN/1194/04 strain. Importantly, all MVTTHA-QH-vaccinations
were completely protected against challenges with pathogenic A/
BhG/QH/1/05 and A/VN/1194/04, respectively (Fig. 5 and 6).
These findings indicated that MVTTHA-QH displayed a potential
to overcome the problem of antigenic drift between clade 1 and
clade 2.2, and therefore, is an attractive target vaccine for further
clinical development. H5 from A/Anhui/2/05 appeared to be a
weak antigen when using MVTT as a vector. This was most likely
caused by mutations inducing conformational changes and hid of
antigenic sites of HA (Table. 1), because the HA protein was
efficiently expressed in MVTT-HA-AH infected Vero cells (Fig. 2),
and MVTTHA-AH was able to induce NT responses after the 2nd
immunization against the Qinghai strain (Fig. 3C). Consistently,
A/Anhui/1/2005 is less sensitive to the neutralizing activity of
MVTT-HA-QH-induced antibodies compared to other H5N1
influenza viruses, including strain A/duck/Fujian/1734/2005,
which also belongs to clade 2.3.4 (Fig. 3 and 4). Two out of five
mice in the oral administration group did not respond to the
MVTT-HA-QH vaccine after two immunizations due to individual
variance.
MVTT-based vaccines offer certain advantages over conven-
tional influenza vaccines. With recent technical improvements, the
time required for constructing MVTT-based vaccines is becoming
significantly shortened. In comparison to adeno-vectored or DNA-
based vaccines, vaccinia delivers a high level of foreign gene
expression directly without time-consuming gene-optimization
procedures [10,13]. Critically, MVTTHA-QH does not depend on
SPF eggs or primary chicken embryo fibroblast [34,35].
MVTTHA-QH can be produced using WHO-recommended Vero
cells with ease and without the requirement of bio-safety level-3
containment, which is necessary for inactivated vaccines. The
large-scale production of MVTTHA-QH is, therefore, feasible.
Given the large capacity for housing large foreign gene inserts, it is
possible to use MVTT to generate a multivalent-H5 vaccine in
order to further improve the breath of cross-clade NT and HI
antibody responses. When compared to the widely-used modified
vaccinia Ankara (MVA) vector [36–41], we recently demonstrated
that MVTT is superior to MVA for inducing high levels of
systemic neutralizing antibodies against SARS coronavirus,
especially through mucosal routes of vaccination [24]. To this
end, we found that intranasal vaccination with MVTTHA-QH
induced consistently high levels of systemic NT and HI antibody
responses that are equivalent to the outcomes of intramuscular
injection. Moreover, intranasal vaccination can overcome pre-
existing anti-vector immune responses, which offers advantages for
the elderly who previously have received VTT against smallpox
[24]. As a non-invasive procedure, intranasal vaccination also has
great implications for mass vaccination of human populations,
especially in developing countries. Lastly, intranasal vaccination
has made it possible to develop MVTTHA-QH as a potential
aerosol veterinary vaccine, which, however, would require efficacy
testing after being sprayed onto poultry and migratory bird
populations. Given these reasons, our findings from this study have
important implications in the fight against possible zoonotic
HPAIV outbreaks.
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